To our knowledge, this study is the first to apply deep learning models that can, beyond diagnosis, identify molecular subtypes and predict outcomes in a single brain tumour entity (meningioma) using ...

As clinical trials grow increasingly complex and multi-modal, the pharmaceutical industry is pivoting toward AI-driven agentic orchestrators and lakehouse architectures to untangle disparate data ...